Fred Hassan stay on as IFPMA head
This article was originally published in Scrip
Fred Hassan, chairman and CEO of Schering-Plough, has been elected to a second two-year term as president of the International Federation of Pharmaceutical Manufacturers and Associations. He was first elected in 2006 to replace Dr Daniel Vasella of Novartis. Haruo Naito, president and CEO of Eisai was re-elected vice-president. David Brennan, CEO of AstraZeneca, has also been elected vice-president, replacing Dr Alessandro Banchi, who is stepping down as an IFPMA officer and retiring from Boehringer Ingelheim at the end of the year. Earlier this year, Alicia Greenidge was named director-general of the association, succeeding Dr Harvey Bale.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.